Oral News and Research

RSS

PERC-led study recognized as one of Canada's top achievements in health research

You could call it paying it forward. A trip to the Emergency Department (ED) is every parent's worst nightmare. But what if the information documented as a result of your child's visit could help a child with similar symptoms a few provinces away? Terry Klassen and his research team of leading pediatric emergency physicians at Pediatric Emergency Research of Canada (PERC) have done just that and the impact of their research is today recognized as one of the Top Canadian Achievements in Health Research in 2011.

24 Jan 2012

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

24 Jan 2012

Multiple sclerosis drug Gilenya under investigation by FDA and EMA

The US Food and Drugs Administration (FDA) and European Medicines Agency (EMA) are looking at the pros and cons of using Gilenya (fingolimod) in treating the neurological autoimmune disease Multiple Sclerosis (MS).

23 Jan 2012

New tool to improve ease of oral fluid collection

Researchers are constantly finding new ways to figure out what makes us human beings tick, and one of the newer methods makes you want to spit—literally. Saliva is full of analytes and biomarkers that create a biological journal of exposure to chemicals and disease, and genetic variability. However, the collection of oral fluid has always proved cumbersome, with researchers depending on swabs or collection cups.

21 Jan 2012

Texas abortion issue back in court today

A Federal judge in Austin holds another hearing on Texas law requiring women seeking an abortion to have a sonogram. Also, NPR looks at the growing number of restrictions across the country.

21 Jan 2012

New data from Infinity saridegib and gemcitabine Phase 1b/2 combination trial on pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced updated data from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of saridegib in combination with the chemotherapy gemcitabine in patients with previously untreated, metastatic pancreatic cancer.

20 Jan 2012

Positive preliminary data from Exelixis' cabozantinib phase 2 trial on HCC

Exelixis, Inc. today reported positive preliminary data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.

20 Jan 2012

Longer looks: Explaining Medicare's 'premium support'

Last month, the U.S. Food and Drug Administration convened a committee of medical experts to weigh new evidence concerning the potential dangers of drospirenone, a synthetic hormone contained in popular birth control pills including Bayer AG's Yaz and Yasmin. ... the committee concluded by a four-vote margin that the benefits of drugs with drospirenone outweigh the risks.

20 Jan 2012

Oral contraceptive pills help relieve period pain: Study

A three decade long study has proven that oral contraceptive pills may alleviate painful periods for some women. Estimates suggest more than half of women have suffered from the condition, called dysmenorrhea, at some point.

19 Jan 2012

Study demonstrates possibility of curing hepatitis C without use of interferon

Bristol-Myers Squibb Company today announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin ('null responders').

19 Jan 2012

New research into treatment, prognosis and early detection of GI cancers

New research into the treatment, prognosis and early detection of gastrointestinal cancers was released today in advance of the ninth annual Gastrointestinal Cancers Symposium being held January 19-21, 2012, at The Moscone West Building in San Francisco, Calif.

19 Jan 2012

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Viread in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2-12.

19 Jan 2012

Bristol-Myers Squibb agrees purchase of Inhibitex for $2.5Bn

American pharmaceutical giant Bristol-Myers Squibb has agreed the purchase of US biotech company Inhibitex, in a $2.5Bn (£1.6bn) deal which includes the promising new anti-hepatitis C drug INX-189, first designed and prepared in Cardiff University.

19 Jan 2012

Watson introduces new oral contraceptive, Vestura

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Pharma, Inc. has launched Vestura(TM), a generic version of Bayer HealthCare Pharmaceuticals Inc.'s Yaz(R) oral contraceptive product.

18 Jan 2012

Cangrelor allows stent patients to be 'bridged' to cardiac surgery

New findings from a research study led by physicians at Scripps Health reveal that the investigational drug cangrelor has the unique properties of achieving very fast blood thinning effects when needed to protect from heart attacks, but also dissipates rapidly so patients can undergo surgery without the excessive bleeding often associated with blood thinning medications.

18 Jan 2012

Ethanol, nonalcoholic compounds in red wine may reduce risk of vascular disease

Observational epidemiologic studies relating wine and alcohol to health all suffer from the fact that they, of necessity, compare people who prefer certain beverages, but not the beverages themselves. While there have been many intervention trials in animals, randomized trials in humans are less common. Randomized crossover trials, in which each subject receives all interventions in sequence, can be especially important as they tend to avoid baseline differences among subjects and can detect effects of different interventions with smaller numbers of subjects.

18 Jan 2012

Dental Lab Products magazine recognizes Objet Eden260V 3D Printer as 2011 Readers' Choice

Objet Ltd., the innovation leader in 3D printing for rapid prototyping and additive manufacturing, today announced that the Objet Eden260V 3D Printer has been recognized as a 2011 "Readers' Choice" by subscribers to Dental Lab Products magazine.

17 Jan 2012

No statistical difference between IO and IV infusion in therapeutic hypothermia

The results of a study conducted by Vidacare Corporation comparing whether Intraosseous (IO) vascular access may be used to infuse chilled saline as effectively as peripheral intravenous (IV) access to achieve therapeutic hypothermia found no statistical difference between the two routes.

17 Jan 2012

Animal study confirms dramatic effects of natural formula against prostate cancer

New animal study confirms the dramatic effects of a natural formula against aggressive prostate cancer tumors. Researchers at the Methodist Research Institute at Indiana University conducted the study on mice, using a human prostate cancer xenograft model.

17 Jan 2012

Combination of lapatinib and trastuzumab more effective in treating HER2-positive breast cancer

Using two drugs that inhibit the growth factor HER2 for preoperative treatment of early-stage HER2-positive breast cancer appears to have better results than treatment with a single agent. In a report in the January 17 issue of The Lancet, an international research team reports that a protocol adding lapatinib (Tykerb) to trastuzumab (Herceptin) was more effective than single-drug treatment with either drug in eliminating microscopic signs of cancer at the time the tumors were surgically removed.

17 Jan 2012